The epidemiology of osteosarcoma Pediatric and adolescent osteosarcoma, pp.3-13, 2009. ,
Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?, Science and Engineering Ethics, vol.24, issue.10, pp.1255-1276, 2016. ,
DOI : 10.1038/nbt1006-1211
Development of individualized anti-metastasis strategies by engineering nanomedicines, Chemical Society Reviews, vol.6, issue.17, pp.6258-6286, 2015. ,
DOI : 10.1371/journal.pone.0019662
URL : http://europepmc.org/articles/pmc4540626?pdf=render
Exploiting the enhanced permeability and retention effect for tumor targeting, Drug Discovery Today, vol.11, issue.17-18, pp.812-818, 2006. ,
DOI : 10.1016/j.drudis.2006.07.005
Cancer active targeting by nanoparticles: a comprehensive review of literature, Journal of Cancer Research and Clinical Oncology, vol.371, issue.4, pp.141-769, 2015. ,
DOI : 10.1016/j.jmb.2007.05.011
URL : https://link.springer.com/content/pdf/10.1007%2Fs00432-014-1767-3.pdf
Phase I/II and Phase II Studies of Targeted Gene Delivery In Vivo: Intravenous Rexin-G for Chemotherapy-resistant Sarcoma and Osteosarcoma, Molecular Therapy, vol.17, issue.9, pp.17-1651, 2009. ,
DOI : 10.1038/mt.2009.126
Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy, Current Pharmaceutical Design, vol.21, issue.42, pp.6104-6124, 2015. ,
DOI : 10.2174/1381612821666151027152534
Genetically Modified T cells Targeting Interleukin-11 Receptor ??-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases, Cancer Research, vol.72, issue.1, pp.72-271, 2012. ,
DOI : 10.1158/0008-5472.CAN-11-2778
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis, Pediatric Blood & Cancer, vol.190, issue.8, pp.61-1362, 2014. ,
DOI : 10.4049/jimmunol.1201314
EMT transcription factors: implication in osteosarcoma, Medical Oncology, vol.9, issue.4, 2013. ,
DOI : 10.1158/1541-7786.MCR-11-0093
Circulating tumour cells: a review of non-EpCAM-based approaches for cell enrichment and isolation ,
DOI : 10.1373/clinchem.2015.249706
URL : http://clinchem.aaccjnls.org/content/clinchem/62/4/571.full.pdf
The challenges of detecting circulating tumour cells in sarcoma, Front Oncol, vol.6, issue.202, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01466092
Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis, International Journal of Molecular Sciences, vol.6, issue.12, p.17, 2016. ,
DOI : 10.3389/fonc.2014.00366
URL : https://hal.archives-ouvertes.fr/inserm-01466086
The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma, Cellular Immunology ,
DOI : 10.1016/j.cellimm.2017.10.011
URL : https://hal.archives-ouvertes.fr/inserm-01644725
Lipid nanoparticles enhance the efficacy of chemotherapy in primary and metastatic human osteosarcoma cells, J. Drug Deliv ,
Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization, European Journal of Pharmaceutics and Biopharmaceutics, vol.68, issue.2, pp.68-207, 2008. ,
DOI : 10.1016/j.ejpb.2007.06.015
Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for antitumoural alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems, J. Chromatogr. Anal. Technol. Biomed. life Sci, vol.23 ,
Protein measurement with the Folin phenol reagent, J. Biol. Chem, vol.193, pp.265-275, 1951. ,
Drugs in early clinical development for the treatment of osteosarcoma, Expert Opinion on Investigational Drugs, vol.50, issue.6, pp.1265-1280, 2016. ,
DOI : 10.1038/srep20944
URL : https://hal.archives-ouvertes.fr/inserm-01466096
Lipid nanoparticles protect from edelfosine toxicity in vivo, International Journal of Pharmaceutics, vol.474, issue.1-2, pp.474-475, 2014. ,
DOI : 10.1016/j.ijpharm.2014.07.053
Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids, British Journal of Cancer, vol.72, issue.2, pp.277-286, 1995. ,
DOI : 10.1038/bjc.1995.325
Daunorubicin and doxorubicin molecular interplay with 2D membrane models, Colloids and Surfaces B: Biointerfaces, vol.160, pp.610-618, 2017. ,
DOI : 10.1016/j.colsurfb.2017.09.058
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells, International Journal of Cancer, vol.63, issue.3, pp.364-371, 2005. ,
DOI : 10.1002/ijc.20602
URL : http://onlinelibrary.wiley.com/doi/10.1002/ijc.20602/pdf
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice, Breast Cancer Research and Treatment, vol.69, issue.5, pp.133-523, 2012. ,
DOI : 10.1124/mol.105.020776